Related Experiment Video
Updated: Apr 5, 2026
10:18
Author Spotlight: Exploring Seaweed's Bioactive Compounds for Sustainable Innovations in Industries
Published on: November 21, 2023
3.7K
Potential Bioactive Compounds from Seaweed for Diabetes Management.
Yusrizam Sharifuddin1,2, Yao-Xian Chin3,4, Phaik-Eem Lim5,6
1Institute of Ocean and Earth Sciences, University of Malaya, 50603 Kuala Lumpur, Malaysia. yusrizam@um.edu.my.
Marine Drugs
|August 27, 2015
Summary
Seaweeds contain bioactive compounds that may help manage Type II diabetes mellitus (T2DM). This review explores seaweed
Area of Science:
- Marine biology
- Nutritional science
- Endocrinology
Background:
- Type II diabetes mellitus (T2DM) is a global health issue driven by lifestyle factors.
- Effective T2DM management requires novel preventive and therapeutic strategies.
- Seaweeds offer rich sources of bioactive compounds with potential health benefits.
Purpose of the Study:
- To review seaweed composition and bioactive compounds for T2DM prevention and management.
- To explore seaweed's mechanisms of action against T2DM.
- To consolidate findings from in vitro, in vivo, and human studies.
Main Methods:
- Literature review of scientific studies on seaweed and T2DM.
- Analysis of seaweed's bioactive compounds and their pharmacological relevance.
- Examination of various proposed mechanisms of action.
Main Results:
- Seaweed compounds target key enzymes like alpha-glucosidase, alpha-amylase, and lipase.
- Mechanisms include anti-inflammatory effects, antioxidant enzyme induction, and glucose transport stimulation.
- Seaweed agents show potential for beta-cell protection and incretin hormone release.
Conclusions:
- Seaweed-derived bioactive compounds present promising avenues for T2DM intervention.
- Further research into seaweed's therapeutic potential for metabolic disorders is warranted.
- Dietary and lifestyle interventions involving seaweeds could aid T2DM management.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
887
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
887
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:16Hormones Regulating Blood Glucose
8.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.6K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
962
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
962
01:06Oral Hypoglycemic Agents: Glinides
961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961